Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
Clinical trial NCT07413601 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07413601
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-10
- Primary completion
- 2029-02-10
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.